HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


P&G To Test ‘Benign Elasticity’ Seen In Q2 With More Pricing Planned

Executive Summary

“A world in which all of the market growth is driven by pricing is obviously not sustainable,” CFO Andre Schulten acknowledged in P&G’s fiscal 2023 second-quarter earnings presentation. The firm remains focused on investing in its brands and driving household penetration while weathering economic headwinds and taking additional pricing in February.

You may also be interested in...

P&G’s Fiscal Third Quarter Buoyed By US Consumer Loyalty, China Recovery

Procter & Gamble Co. reports net sales in the fiscal third quarter advanced 4% reported, 7% organically. US consumers are sticking with the firm’s brands, including Pantene and Vick’s, despite higher pricing taken through March, while China shows steps in recovery with 2% organic growth in the quarter.

US Q1 Consumer Health Earnings Preview: Lifted By Welcome Changes, Or Slowed By Surprises?

An end to US COVID-19 PHE on 10 April doesn’t end inflationary pressure on prices for consumer packaged goods. OTC, supplements and personal care product firms could be reporting consumers during Q1 were going along with price increases, opting for less expensive options or buying less.

P&G Looks To Change Children’s Toothpaste Market With Crest Kids Color Changing

Color of the toothpaste, which P&G North America oral care chief says is “only one of its kind on the market today,” changes from blue to pink after two minutes of brushing.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts